Keros Therapeutics Inc (KROS)

NASDAQ
37.75
-0.15(-0.40%)
  • Volume:
    94,196
  • Bid/Ask:
    20.00/45.36
  • Day's Range:
    36.22 - 39.20

KROS Overview

Prev. Close
37.9
Day's Range
36.22-39.2
Revenue
-
Open
37.92
52 wk Range
25.71-88.8
EPS
-2.27
Volume
94,196
Market Cap
879.46M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
-
P/E Ratio
-
Beta
-
1-Year Change
39.61%
Shares Outstanding
23,296,930
Next Earnings Date
Nov 16, 2021
What is your sentiment on Keros Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Keros Therapeutics Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellStrong SellSell
Technical IndicatorsStrong BuyBuyStrong SellStrong SellStrong Sell
SummaryStrong BuyNeutralStrong SellStrong SellStrong Sell

Keros Therapeutics Inc Company Profile

Keros Therapeutics Inc Company Profile

Employees
38

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. Its protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (MDS) and myelofibrosis. Its small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressive. KER-047 is in a Phase I clinical trial. Its KER-012 is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.